Nanotechnology Now

Our NanoNews Digest Sponsors







Heifer International

Wikipedia Affiliate Button


Home > Press > PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

Abstract:
PDS Biotechnology Corporation today announced that the company has been selected as a collaborator of the US National Cancer Institute's Nanotechnology Characterization Lab (NCL) to complete preclinical development of Versamune(TM)-HPV prior to filing of the Investigational New Drug Application. The NCL will perform selected physical, chemical and biological studies on behalf of the company at its facilities at the National Cancer Institute (NCI) in Frederick, Maryland. Dr. Frank Bedu-Addo, President of the Corporation stated that, "PDS Biotechnology Corporation's partnership with the NCL provides significant value to the company. The invaluable expertise of the NCL's scientists will provide the company with additional expert resources and technologies, and will facilitate rapid development of the product."

PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

CINCINNATI, OH | Posted on November 6th, 2008

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology Corporation was awarded in August 2008, a phase I SBIR grant by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-Melanoma to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology Corporation's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen- presenting cells of the immune system and simultaneously acts a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation (www.pdsbiotech.com) is a Cincinnati, Ohio-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

The NCL is a formal collaboration between the US National Cancer Institute, the US Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST) to rapidly advance promising cancer nanotechnology drugs through regulatory submissions with the FDA.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
3130 Highland Avenue
Third Floor
Cincinnati, Ohio 45219
Tel: 513-475-6610
Fax: 513-221-1891

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Sound waves precisely position nanowires June 19th, 2013

Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013

Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013

Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013

Laboratories

Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013

Discovery of new material state counterintuitive to laws of physics June 14th, 2013

New quantum dot technique combines best of optical and electron microscopy June 12th, 2013

Exposure to Air Transforms Gold Alloys Into Catalytic Nanostructures: Brookhaven Lab scientists create promising gold-indium oxide nanoparticles through room-temperature oxidation June 12th, 2013

Govt.-Legislation/Regulation/Funding/Policy

Sound waves precisely position nanowires June 19th, 2013

3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013

Working backward: Computer-aided design of zeolite templates: Rice scientists apply drug-design lessons to production of industrial minerals June 17th, 2013

An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013

Nanomedicine

Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013

3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Appointments/Promotions/New hires/Resignations/Deaths

Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013

SEMATECH Names William R. Rozich Chairman of the Board June 13th, 2013

David Neuschuler Joins RASIRC to Manage Engineering June 3rd, 2013

Asylum Research Announces Ben Ohler as AFM Business Manager May 29th, 2013

Alliances/Partnerships/Distributorships

Imec presents 4K2K CMOS image sensor together with Panasonic: The co-developed imager sensor chip targets high speed, high resolution imaging applications such as next generation HDTV June 18th, 2013

European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013

SEMATECH to Address Critical Supply Chain Challenges and Present Latest Technology Advances at SEMICON West 2013 June 17th, 2013

SEMATECH Names William R. Rozich Chairman of the Board June 13th, 2013

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project








abbigliamento uomo
Computer Accessories
© Copyright 1999-2013 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE